Claims for Patent: 5,132,287

Summary for Patent: 5,132,287

Title:	Methods of treating disorders which cause conglutinin deficiency
Abstract:	Human conglutinin, polyclonal, and monoclonal antibodies raised against human conglutinin, and their uses in therapy and diagnosis are described. Human conglutinin was obtained from human plasma by affinity chromatography with anti-bovine conglutinin antibody, has a relative molecular weight of 330 and 40 K unreduced and 66 K reduced as measured by SDS-PAGE, shows calcium-dependent and sugar inhibitable binding to complement-reacted immune complexes and zymosan, and immunological cross-reaction with anti-bovine conglutinin antibody.
Inventor(s):	Jensenius; Jens C. (Odense M, DK)
Assignee:	Novo Industri A/S (DK)
Application Number:	07/441,792
Patent Claims:	1. A method of treating disorders in human subjects, wherein said disorders cause a conglutinin deficiency, said method comprising the administration to said human subjects of therapeutically effective amounts of human conglutinin in substantially pure form comprising a plasma protein of monomeric molecular weight of 40,000 daltons in the unreduced state and 66,000 daltons in the reduced state, and a polymeric relative molecular weight of 330,000 daltons in the unreduced state, said protein comprising in the monomeric reduced state the following amino acid composition: said protein exhibiting calcium-dependent and sugar-inhibitable binding to complement-reacted immune complexes and zymosan, and said protein being sensitive to collagenase digestion. 2. A method of treating human subjects for microbial infections, wherein said microbial infections cause a conglutinin deficiency, said treating comprising the administration to said human subjects of therapeutically effective amounts of human conglutinin in substantially pure form comprising a plasma protein of monomeric molecular weight of 40,000 daltons in the unreduced state and 66,000 daltons in the reduced state, and a polymeric relative molecular weight of 330,000 daltons in the unreduced state, said protein comprising in the monomeric reduced state the following amino acid composition: said protein exhibiting calcium-dependent and sugar-inhibitable binding to complement-reacted immune complexes and zymosan, and said protein being sensitive to collagenase digestion. 3. The method of claim 2 wherein said administration is prophylactic. 4. The method of claim 2 wherein said administration is ameliorative. 5. The method of claim 2 wherein said administration is curative. 6. A method of treating human subjects with conglutinin deficiencies, said treatment to restore normal levels of conglutinin, comprising the administration to said human subjects of therapeutically effective amounts of human conglutinin in substantially pure form comprising a plasma protein of monomeric molecular weight of 40,000 daltons in the unreduced state and 66,000 daltons in the reduced state, and a polymeric relative molecular weight of 330,000 daltons in the unreduced state, said protein comprising in the monomeric reduced state the following amino acid composition: said protein exhibiting calcium-dependent and sugar-inhibitable binding to complement-reacted immune complexes and zymosan, and said protein being sensitive to collagenase digestion.

Details for Patent 5,132,287

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2009-07-21